Loading…
Develops complement inhibitor antibodies for severe autoimmune and rare inflammatory diseases.
Develops complement inhibitor antibodies for severe autoimmune and rare inflammatory diseases.
Has no approved product and no sales; it funds its trials by selling new shares and could later be paid through sales of an approved drug or through licensing deals. It became a public company in 2023 by merging with Magenta Therapeutics, an already-listed biotech.
Moat: none (IP / patents). Clinical-stage biotech with patent-protected antibody candidates but no approved products or revenue yet.
Headquarters: New York City, US · Founded: 2022 · Employees: 92
Size Dianthus Therapeutics (DNTH) is a United States Health Care company (Biotechnology) with a market value of $4.81B, the 1211th largest of 3,117 United States companies the cockpit tracks. Shares closed at $86.03 on 6 Nov 2026.
Performance Over six months the shares fell 0.8%, against +2.0% for the median peer and -1.1% for the United States market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue fell 60.8% over the last twelve months (peer median +9.9%); the operating margin is -11,441.4% (peer median -7.8%).
Valuation It trades at 2,087.9× enterprise value to sales against a peer median of 12.4× (most expensive of 15).
Capital Return on invested capital runs 63.5 points below its cost of capital (12.2% WACC).
Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.90M | $2.04M | $6.24M | $2.83M | $6.42M |
| Revenue growth | — | -67% | +121% | -56% | — |
| Gross profit | $1.52M | $1.61M | $5.82M | $2.47M | $6.27M |
| EBITDA | -$217M | -$178M | -$101M | -$47.8M | -$29.6M |
| Net income | -$192M | -$162M | -$85.0M | -$43.6M | -$28.5M |
| Free cash flow | -$156M | -$129M | -$78.3M | -$37.0M | -$29.2M |
| Capital expenditure | $334,000 | $213,000 | $105,000 | $110,000 | $139,000 |
| Total debt | $1.29M | $1.39M | $1.49M | $585,000 | $788,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Dianthus Therapeutics DNTH | $4.81B | -1% | -61% | -11,441% | 2,087.9× | n/a |
| AstraZeneca AZN.L | $291B | +1% | +5% | 23% | 5.1× | 14.5% |
| argenx SE Sponsored ADR ARGX | $57.5B | +19% | +71% | 29% | 10.0× | 10.9% |
| Immunovant IMVT | $6.31B | +5% | n/a | n/a | n/a | n/a |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 7.0× | 3.5% |
| Regeneron Pharmaceuticals REGN | $93.5B | +27% | +19% | 30% | 5.2× | -2.2% |
| Amgen AMGN | $249B | +40% | +9% | 36% | 7.4× | 1.8% |
| Annexon ANNX | $796M | -26% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DNTH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.4% | +2.1% | 10th highest of 21 |
| 6-month return | -0.8% | +2.0% | 11th highest of 21 |
| Distance from 52-week high | -27.0% | -23.5% | 9th lowest of 21 |
| Revenue growth (TTM) | -60.8% | +9.9% | lowest of 15 |
| Operating margin | -11,441.4% | -7.8% | lowest of 15 |
| EV / Sales | 2,087.9× | 12.4× | most expensive of 15 |
| ROIC minus cost of capital | -63.5 pp | -10.6 pp | 2nd lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics DNTH | United States | $4.81B | -1% | -61% | -11,441% | 2,087.9× | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $4.86B | -9% | -34% | -2,059% | 133.6× | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.89B | -11% | -22% | 17% | 5.7× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.89B | +28% | n/a | n/a | n/a | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.72B | -37% | +8% | -35% | 14.5× | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.92B | -34% | +102% | 61% | 1.2× | n/a | n/a |
| Joinn Laboratories (China) 603127.SS | China | $4.58B | +15% | +12% | -4% | 15.1× | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.51B | -13% | -18% | -1% | 2.8× | 32.2% | +7.1% |
| Adaptive Biotechnologies ADPT | United States | $4.47B | +103% | +50% | -12% | 14.7× | n/a | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.35B | -2% | -28% | -210% | 5.4× | -6.4% | -10.0% |
| Anthem Biosciences ANTHEM.NS | India | $5.46B | +17% | -1% | 35% | 24.9× | 36.7% | +26.2% |
| Cogent Biosciences COGT | United States | $5.49B | -9% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 300347.SZ | China | $5.58B | -6% | +16% | 10% | 5.4× | 28.4% | +16.4% |
| Relay Therapeutics RLAY | United States | $4.08B | +46% | +24% | -2,999% | 308.8× | n/a | n/a |
| Scholar Rock SRRK | United States | $5.72B | -3% | n/a | n/a | n/a | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.85B | +149% | +101% | -340% | 51.7× | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.76B | -11% | -13% | 21% | 4.8× | 3.2% | +12.5% |
| Lin BioScience 6696.TWO | Taiwan | $3.74B | +129% | n/a | n/a | n/a | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.24B | +142% | n/a | n/a | n/a | n/a | n/a |
| Immunovant IMVT | United States | $6.31B | +5% | n/a | n/a | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.64B | +64% | +35% | -91% | 10.4× | n/a | n/a |